According to Frost & Sullivan, China's pharmaceutical R&D investment is projected to reach USD 52.9 billion by 2026. Amid accelerated restructuring of the pharmaceutical industry, expedited regulatory reviews, and dynamic adjustments to the national medical insurance catalog, domestic pharmaceutical companies are transitioning from generic drugs to innovative drug development, achieving remarkable breakthroughs and progress globally. However, as issues such as homogeneity in innovative drug R&D become increasingly prominent and competition intensifies, more pharmaceutical enterprises are turning their attention to overseas markets in search of broader development opportunities and greater returns.

To assist pharmaceutical companies in selecting better pathways for global expansion and proactively addressing the opportunities and challenges brought by evolving regulations, technologies, and strategies, the "Formulation Zone of the 23rd World Pharmaceutical Raw Materials China Exhibition (CPHI China 2025)" will be held from June 24 to 26, 2025, at the Shanghai New International Expo Center. The event will feature experts from domestic and international regulatory agencies and pharmacopoeia committees, who will interpret the latest regulatory policies and analyze market development trends. Additionally, experts and industry leaders from leading enterprises will share global expansion strategies and success stories, helping companies unlock new business models, enhance their capabilities in bringing innovative drugs to international markets, and strengthen the influence and competitiveness of China's pharmaceutical industry in the global arena.